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ABSTRACT
The pharmacological disruption of the interaction
between the HIV Tat protein and its cognate trans-
activation response RNA (TAR) would generate
novel anti-viral drugs with a low susceptibility to
drug resistance, but efforts to discover ligands
with sufficient potency to warrant pharmaceutical
development have been unsuccessful. We have pre-
viously described a family of structurally con-
strained b-hairpin peptides that potently inhibits
viral growth in HIV-infected cells. The nuclear
magnetic resonance (NMR) structure of an inhibitory
complex revealed that the peptide makes intimate
contacts with the 3-nt bulge and the upper helix of
the RNA hairpin, but that a single residue contacts
the apical loop where recruitment of the essential
cellular co-factor cyclin T1 occurs. Attempting to
extend the peptide to form more interactions with
the RNA loop, we examined a library of longer
peptides and achieved >6-fold improvement in
affinity. The structure of TAR bound to one of the
extended peptides reveals that the peptide slides
down the major groove of the RNA, relative to our
design, in order to maintain critical interactions with
TAR. These conserved contacts involve three amino
acid side chains and identify critical interaction
points required for potent and specific binding to
TAR RNA. They constitute a template of essential
interactions required for inhibition of this RNA.
INTRODUCTION
HIV-1 TAR is a stem–loop RNA found at the 50 end of all
nascent viral transcripts (Figure 1). The cooperative
binding of the viral protein Tat and its cellular co-factor
cyclin T1 to TAR recruits and activates the CDK9 kinase
to hyperphosphorylate RNA polymerase II, leading to
greatly enhanced processivity of the polymerase (1,2). If
the Tat–TAR–cyclin complex does not form, the polymer-
ase produces primarily short transcripts and viral replica-
tion is inefﬁcient. In the past decade or two, many groups
have identiﬁed small molecule and peptide mimetic ligands
for TAR (3–19), but none had sufﬁcient potency and spe-
ciﬁcity to warrant pharmaceutical development. We have
previously used structure-based design methods to
discover cyclic peptide structural mimics of Tat protein
with nM afﬁnity for HIV TAR (20–23). These molecules
inhibit viral replication in primary human lymphocytes
with activity only 10-fold lower than the non-nucleoside
reverse transcriptase inhibitor nevirapine (manuscript in
preparation). They are active against viral isolates from
each of the HIV-1 clades and are not cytotoxic to at least
1-mM concentrations. The peptides are conﬁned to their
cyclic b-hairpin structure by a D-Pro-L-Pro hairpin-
promoting template (24). Their constrained cyclic struc-
ture stabilizes them against proteolysis, and mechanistic
studies show that the compounds inhibit early steps in
reverse transcription as well as Tat-dependent HIV tran-
scription (manuscript in preparation). These characteris-
tics make the peptides exciting antiviral leads, but their
activity must be improved before they can be further
explored as drug candidates.
The nuclear magnetic resonance (NMR) structure of the
lead peptide L-22 (Table 1, Figure 2a) bound to TAR has
been reported (23). It reveals that the peptides bind TAR
in the major groove of the upper RNA helix (nucleotides
26–29 and 36–39) with the D-Pro-L-Pro template facing
down towards the lower helix. Interactions important for
peptide afﬁnity and selectivity can be grouped into three
categories: stacking with residue A35 of the apical loop of
TAR that wraps the RNA around the solvent-exposed
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face of the peptide; hydrophobic contacts that drive for-
mation of a base triple between bulge residue U23 and
base pair A27-U38 in the upper helix; and the stabilization
of the base triple by charged residues binding near the
interhelical junction. Based on these features, we
hypothesized that the peptide binding activity could be
improved by lengthening the b-hairpin to establish more
extensive contacts with the apical loop of the RNA.
In order to test this hypothesis, we synthesized a small
library of 25 peptides containing 1, 2 or 4 additional
amino acids and tested their binding to TAR RNA.
Successful motifs were combined in a follow-up library
of 12 peptides. One of these peptides, KP-Z-41, emerged
as the lead molecule among these extended peptides due to
its afﬁnity for TAR and the quality of NMR data for its
complex with TAR RNA. We determined the structure of
this complex by NMR and observed that contacts near the
interhelical junction remain almost unchanged between
this structure and our previous L-22 structure, while the
contacts to the loop and RNA backbone re-position them-
selves to accommodate the interactions at the junction.
This was unexpected from our structure-based design,
and this interaction positions the peptide further down
the major groove, away from the apical loop, than we
had predicted. Thus, while we were unsuccessful in extend-
ing the peptide toward the apical loop, the structure
identiﬁes a small set of essential interactions that are
critical for recognition of HIV-1 TAR and could be ex-
ploited for the design of small molecule peptidomimetics.
METHODS
Peptide and RNA synthesis
The synthesis of the cyclic peptides was conducted as
described previously (20,22). HIV-1 TAR RNA was
prepared in vitro from commercially synthesized DNA
templates (IDT) using in-house-puriﬁed T7 RNA poly-
merase and unlabeled nucleotides (Sigma), or 98% 15N,
13C labeled nucleotides (Cambridge Isotope Labs), or
98% deuterated nucleotides (Isotec). RNA products
were separated by denaturing polyacrylamide gel electro-
phoresis. The desired RNA was excised from the gel and
further puriﬁed by electroelution, desalting on a NAP-10
column (GE Healthcare), and extensive dialysis against a
10mM potassium phosphate buffer, pH 6.6, with 0.1mM
EDTA (25,26). Prior to NMR, RNA products were
exchanged into 99.99% D2O by lyophilization, and then
annealed with heating to 90C and quick cooling on ice.
Preparation of radiolabeled RNA and gel shift assays
T4 RNA ligase (Promega) and cytidine 30,50-
bis[alpha-32P]phosphate, triethylammonium salt (pCp,
GE Healthcare) were used to label puriﬁed HIV-1 TAR
RNA. Free pCp remaining in solution after the ligation
was largely removed by passing the RNA solution
through a NAP-10 desalting column (GE Healthcare).
The RNA was annealed by heating to 90C, followed by
quick cooling on ice. For each gel shift assay, peptides
were incubated on ice for 30min with labeled TAR and
assay buffer (0.05M Tris–HCl, 0.05M KCl, 0.2M DTT,
1% Triton X-100, and tRNA at 10mg/ml). Samples were
then fractionated by native polyacrylamide gel electro-
phoresis (PAGE) at 15W and 4C in 0.5TB buffer.
Dried gels were exposed to a phosphor imaging plate
and viewed with a Molecular Dynamics scanner. Images
were analyzed with ImageQuant software.
NMR spectroscopy and spectral assignments
NMR spectra were collected on Bruker 500 and 600MHz
spectrometers equipped with cryo-cooled probes. Data
were processed with NMRPipe (27) and analyzed in
Sparky (28). NOESY experiments were recorded at
multiple mixing times (80—300ms) at either 25C (D2O)
or 4C (H2O). The 2D
13C ﬁltered NOESY and TOCSY
spectra of the ‘F1fF2f’ type (29) were collected to facilitate
assignments of peptide resonances. Spectra using partially
perdeuterated RNA (with only H6/8, H2, H10 and H20
protons present) had sharper line widths that facilitated
NOE assignments (SI Figure 1). Resonance assignments
started from those already available for the previous L-22/
HIV-1 TAR RNA complex (23) and were extended to this
new complex using HCCH-COSY, HCCH-TOCSY and
HSQC-NOESY experiments. Initial proton assignments
for the peptide were made from F1fF2f NOESY spectra
and based on the observation of the typical Ha(i) to
HN(i+1) pattern of NOEs common in b-sheets, then
completed with the partially perdeuterated RNA that
removed much of the overlap between peptide and sugar
resonances.
Structure determination
Structures of the HIV-1 TAR RNA/KP-Z-41 complex
were calculated with Xplor-NIH (30) using the experimen-
tal restraints summarized in Table 2. Loose restraints on
backbone dihedral angles (±40) were introduced for
base-paired regions in both helical stems based upon un-
ambiguous spectroscopic veriﬁcation of an A-form RNA
conformation as determined from the pattern of
Figure 1. (a) Sequence and secondary structure of the HIV-1 TAR
RNA construct used in these studies, numbered according to the
start of transcription of the viral RNA and (b) sequences of the lead
peptides L-22 and KP-Z-41 (LP=L-Pro and DP=D-Pro). The dotted
line indicates a disulﬁde bridge.
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Figure 2. (a) Structures of the HIV-1 TAR/L-22 complex (left) and the HIV-1 TAR/KP-Z-41 complex (right). The sequences of the cyclic peptides
are shown in Figure 1. The orientation of the peptide in the RNA major groove is the same in both structures. Common interaction sites are
highlighted with arrows: the lysines that point toward the interhelical junction (black), the arginines that stack over the base triple (red), and the
isoleucines that anchor the peptide in the major groove (blue). (b) Superposition of 10 lowest energy structures for the RNA (left) and cyclic peptide
(right): guanosines are in purple, cytosines in black, adenosines in red, uracils in gray and the peptide is in orange.
Table 1. Sequences of the lead peptides L-22 and KP-Z-41 and summary of their binding activities against HIV-1 TAR RNA (Kd values are in
nanomolar), as determined by EMSA in the absence of competitor tRNA
Mimetic Residue Kd (HIV)
L-22 R1 V2 R3 T4 R5 K6 G7 R8 R9 I10 R11 I12 30
KP-Z-41 R1 V2 R3 C4 R5 Q6 R7 K8 G9 R10 R11 I12 C13 I14 R15 I16 1
Residues are aligned in the table to represent similarity in position upon binding HIV-1 TAR.
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cross-peaks in TOCSY and NOESY spectra (25), while
backbone dihedral angle restraints for the peptide were
derived with TALOS (31). The ﬁnal 10 converged struc-
tures of the complex were selected from the population of
structures with no NOE restraint violations >0.5 A˚ and
had the lowest violations of all experimental restraints.
RESULTS
Based on the interactions between the peptide and TAR
observed in our previous peptide structure and the results
of our mutational studies, we synthesized a small library
of new peptides containing 1, 2 or 4 additional amino
acids. Selected peptides from this initial set are listed in
Table 3 and are named KP-Z-01 through KP-Z-22 for ease
of reference. All peptides were cyclized using the
D-Pro-L-Pro template, and the majority of these new
peptides incorporate two central cysteine residues
forming a disulﬁde bridge to further stabilize the hairpin
fold. Peptides were tested by electrophoretic mobility shift
assay (EMSA) in the presence of 10 000-fold excess tRNA
to establish their afﬁnity and selectivity for TAR RNA.
Peptides containing 16 and 18 amino acids were more suc-
cessful than those containing 15 amino acids, of which
three out of four peptides showed no afﬁnity for TAR
even at the highest concentration tested (5 mM). This
result can conﬁdently be attributed to less stable
b-hairpin formation in the cyclic peptides containing an
odd number of residues. Previous studies of our initial
b-hairpin peptides have shown that stability of the
hairpin in solution is necessary to observe strong afﬁnity
for TAR (20,22). Even the 16-amino acid peptides bound
with only high nanomolar afﬁnity to TAR; this repre-
sented a signiﬁcant loss of activity from our previous
success with L-22. It was also disappointing to see that
even signiﬁcant changes in sequence resulted in minimal
changes in afﬁnity. For example, swapping the K-R-K
motif near the hairpin turn of KP-Z-16 for R-K-R in
KP-Z-17 changed the afﬁnity of the peptide by less than
two-fold. Even exchanging residues across the hairpin
(compare for example KP-Z-19 and KP-Z-20) yielded
almost no change in afﬁnity. These results suggest that
binding of the 16-amino acid peptides may be largely
charge-mediated and is not likely to be very selective.
In the case of the 18-amino acid peptides, many encour-
agingly showed mid-nanomolar activity, even in the
presence of a 10 000-fold excess of tRNA. Furthermore,
small changes in sequence yielded signiﬁcant changes in
activity against TAR in some cases, indicating speciﬁc
binding for this group of peptides. For example, the dif-
ference between KP-Z-05 and KP-Z-06 is only an
exchange of residues at positions 6 and 7, but this rather
small change alters binding from 150 nM to undetectable
at the highest concentration tested (>5 mM). A similar
change from KP-Z-10 to KP-Z-11 yields a comparable
result. The sequence of KP-Z-02, one of the most success-
ful peptides from the library, has an Arg-DArg motif at
positions 7 and 8; changing these Arg to Leu-Lys in
KP-Z-01 abolishes binding even at the highest concentra-
tion tested.
Encouraged by the speciﬁc binding suggested by these
results, we decided to pursue the optimization of the
18-amino acid peptides by rational design. Successful
motifs from these peptides and the reported L-22/TAR
structure were combined in a small follow-up library
(Table 3, KP-Z-33 through KP-Z-40). One of these
peptides, KP-Z-40, emerged as the most potent peptide
with an apparent binding constant of 25 nM, when
measured in the presence of 10 000 fold excess of tRNA
competitor, and Kd <1 nM (when measured in a direct
binding assay in the absence of any tRNA). This result
represents a >6-fold improvement in afﬁnity over the
previous lead peptide L-22.
The structure of L-22 showed that the Ile methyl groups
on one face of the peptide were important for locking the
peptide in the major groove of TAR (23). With this in
mind, we designed a new peptide KP-Z-41, based on the
sequence of KP-Z-40 but with an additional Ile at position
12 in place of the Ala found in the original peptide. The
afﬁnities of KP-Z-40 and KP-Z-41, determined by EMSA
(Figure 3) were similar, but the NOESY experiments for
KP-Z-41 revealed a much greater number of intermolecu-
lar NOEs. For this reason, the KP-Z-41/TAR complex
was selected for structure determination to better under-
stand how increased afﬁnity was obtained.
Hydrophobic interactions promote formation of a base
triple and anchor the peptide in the major groove
The structure contains a base triple between bulge residue
U23 and the A27/U38 base pair, as also observed for
L-22. The NOE data indicate a canonical pairing for
U23 and A27 in the base triple; both A27 amino
hydrogen atoms are protected from solvent exchange
and observable in NOESY experiments. Formation of
the base triple upon binding is likely driven by burial of
the Ile12 methyls against U23, analogous to the
Table 2. Experimental restraints and structural statistics for structure
determination of the KP-Z-41/TAR complex
Total number of restraints 774
NOE-derived restraints 498
intermolecular NOEs 61
RNA (intramolecular) 228
Peptide (intramolecular) 209
Dihedral restraints 192
Hydrogen-bonding restraints 72
Planarity restraints 12
Average rmsd values from experimental restraints
Distance (A˚) 0.06
Dihedral (deg) 0.49
Average rmsd values from ideal geometries
bonds (A˚) 0.004
Angles (deg) 0.91
Improper (deg) 0.73
Heavy atom rmsd from mean structure (A˚)
KP-Z-41 (all backbone atoms) 0.29
KP-Z-41 (all heavy atoms) 1.19
TAR RNA (all heavy atoms) 0.49
TAR RNA core (G18-U23, G26-C29, G36-C44) 0.29
KP-Z-41 and TAR core 0.75
Entire structure 2.1
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interactions of Ile10 in the L22-TAR complex (Figure 4a)
and Ile79 in our original model system of BIV Tat/TAR
(21). Ile14 is also protected from solvent by burial in the
major groove, similar to Ile12 in the L-22 peptide.
Placement of these large hydrophobic side chains on the
peptide backbone orients the correct face of the peptide
toward the RNA and induces formation of the base triple;
thus, location of the hydrophobic residues on the peptide
is one of the most crucial elements for afﬁnity to the TAR.
The peptide KP-Z-41 contains three isoleucine residues at
positions 12, 14 and 16. However, only Ile12 and Ile14 are
located in the RNA major groove, forcing the
D-Pro-L-Pro end of the template to extend away from
the RNA into solution. We had originally hypothesized
that Ile14 and Ile16 would be the hydrophobic groups
docked in the major groove near the base triple, with
Ile12 and the Lys8-Gly9 turn extending up the groove
toward the apical loop instead. However, the structure
reveals that, while burial of these hydrophobic groups is
important for orienting the correct face of the peptide
toward the RNA, their placement within the structure is
also governed by key peptide-RNA polar interactions, as
discussed below. In order to form these polar interactions
at the inter-helical junction, the peptide must slide down
the major groove relative to our design, leaving Ile12 and
Ile 14 docked in the pocket formed in the major groove
upon peptide binding.
Interactions between polar side chains and the bulge
region of TAR position the peptide relative to the RNA
Two important interactions between polar side chains and
the RNA can be seen near the TAR bulge. The
guanidinium group of Arg7 lies over U23 and stabilizes
the base triple (Figure 4b). At the same time, the charged
terminus of Lys8 is favorably oriented by the positioning
of Arg7 and anchor residue Ile12 (as discussed above)
toward a pocket of negative charge formed by the phos-
phate groups of nucleotides C24 through G28 at the
interhelical junction (Figure 4c). The roles of Arg7 and
Lys8 in KP-Z-41 are nearly identical to those of Arg5
and Lys6 in L-22. This Arg-Lys combination, along with
the hydrophobic residue buried beside the base triple,
appear to be the best maintained features between the
two structures. Other interactions adjust themselves to
keep these contacts intact. These two polar interactions
alter the way the peptide contacts the apical loop, as dis-
cussed in the following section, and force the D-Pro-L-Pro
motif and adjacent residues to slide down the major
Table 3. Sequences of selected peptides and summary of their activities against HIV-1 TAR RNA (Kd values are in nM), as determined by
EMSA in the presence of competitor tRNA
Mimetic Position Kd (nM) Error (nM)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
KP-Z-01 R V R C R K L K G Q T R C I R I >5000
KP-Z-02 R V R C R K R DR G Q T R C I R I 75 ±25
KP-Z-03 R V R C R Q R G P G K R C I R I >5000
KP-Z-04 R V R C R K Q G P G T R C I R I >5000
KP-Z-05 R V R C R R K G P G Q R C I R I 150 ±50
KP-Z-06 R V R C R K R G P G Q R C I R I >5000
KP-Z-07 R C R V R Q R K G R A R K I C I 150 ±50
KP-Z-08 R C R V R K Q G P G T R K I C I >5000
KP-Z-09 R C R V R K Q G P G K R K I C I >5000
KP-Z-10 R C R V R K R G P G Q R K I C I >5000
KP-Z-11 R C R V R R K G P G A R K I C I 200 ±50
KP-Z-12 R V R C R R R G R C I R I >5000
KP-Z-13 R V R C R K K DP K C I R I >5000
KP-Z-14 R V R T R K K DP K R I R I 750
KP-Z-15 R V R V R K K G R T I R I >5000
KP-Z-16 R V R C R K R K G R C I R I 500
KP-Z-17 R V R C R R K R G R C I R I 300
KP-Z-18 R V R T R Q R K G R R I R I 200 ±50
KP-Z-19 R V R V R K R K G R Q I R I 250 ±50
KP-Z-20 R V R Q R K R K G R V I R I 200 ±50
KP-Z-21 R V R C R K R K DP R C I R I 300
KP-Z-22 R V R C R T R G K R R R C A R V 200 ±50
KP-Z-33 R V R C R K R R G Q T R C I R I 100 ±25
KP-Z-34 R V R C R K R K G Q T R C I R I 100 ±25
KP-Z-35 R V R T R K R DR G Q T R A I K I 150 ±50
KP-Z-36 R C R V R K R DR G Q T R R I C I 200 ±50
KP-Z-37 R C R V R R K K G R A R K I C I 200 ±50
KP-Z-38 R C R V R Q R G P G A R K I C I >1000
KP-Z-39 R V R C R T R K G R A R C I K I 75 ±25
KP-Z-40 R V R C R Q R K G R R A C I R I 25 ±10
KP-Z-41 R V R C R Q R K G R R I C I R I 75 ±25
All peptides are cyclized with a D-Pro-L-Pro motif not listed here to simplify the table.
Lower-case letters indicate D-amino acids.
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groove and extend away from the RNA, contrary to what
we had expected in the rational design of the longer
peptide library.
The cyclic peptide contacts the apical loop of TAR in a
novel manner
A promising feature of these b-hairpin peptides for RNA
speciﬁcity is their ability to simultaneously contact
multiple unique secondary structure elements of the
RNA. In the L-22/TAR complex, the Arg11 guanidinium
group stacks on the base of loop residue A35, and this
interaction pulls the apical loop to partially close around
the RNA. An interaction with A35 is present for KP-Z-41
as well, but the contact is different, because the space
occupied by Arg11 in the L-22 peptide is replaced by a
Cys in KP-Z-41. Nevertheless, the contact to the loop is of
such importance that the RNA adjusts itself to maintain
Figure 4. (a) Comparison of the hydrophobic interactions observed in the HIV-1 TAR/KP-Z-41 complex (top) and in the HIV-1 TAR/L-22 complex
(bottom) that stabilize the U23-A27-U38 base triple. The peptide L-22 penetrates deeper into the major groove compared to KP-Z-41, and thus the
Ile residue in L-22 is in closer proximity to the base triple than in KP-Z-41. The RNA is represented as a gray surface with nucleotides of interest in
purple, the peptide is in orange and the van der Waals surface of the Ile side chain is represented in dots. (b) An arginine guanidinium group stacks
on top of the U23 base to provide a cation-p interaction that stabilizes the base triple in both the KP-Z-41/TAR complex (top) and the L-22/TAR
complex (bottom). (c) The charged terminus of Lys8 is oriented toward a pocket of negative charge formed by the phosphate groups of nucleotides
C24 through G28 at the interhelical junction. (d) The direct stacking between A35 and an arginine residue that is seen in the L-22/TAR complex
(bottom) is replaced in this new complex by a different set of loop-peptide interactions. The base of G34 is instead ﬂipped out from the RNA loop
and sandwiched between A35 and Arg11 in the KP-Z-41/TAR complex (top).
Figure 3. Comparison of binding results for several peptides from the KP-Z library (all concentrations are in nM) to HIV TAR (1 nM) by electro-
phoretic mobility shift assay (EMSA); the buffer contains a 10 000 fold excess of tRNA to disfavor binding of peptides that form nonspeciﬁc
interactions.
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the interaction. Instead of direct stacking between A35
and an arginine residue, the base of G34 is ﬂipped out
from the rest of the RNA and sandwiched between A35
and Arg11 of KP-Z-41 (Figure 4d). In this new arrange-
ment, G34 completes the Arg–A35 interaction previously
seen in L-22.
Comparison of NOESY data for complexes of lead
peptides KP-Z-40 and KP-Z-41 with HIV-1 TAR RNA
As mentioned previously, cyclic peptide KP-Z-40 has the
strongest afﬁnity for the TAR RNA based on EMSA
results, but the NOE data for this peptide-RNA
complex were of lower quality than for KP-Z-41, so that
the latter peptide was selected for structure determination.
Comparison of the intermolecular NOEs for both
complexes reveals strong similarities for cross-peaks
deﬁning the peptide contact to the apical loop.
Speciﬁcally, NOEs between Val2 and A35, Arg10 and
G34 and Arg11 and G34 are present for both complexes.
These pairings represent several of the most intense inter-
molecular NOEs for the KP-Z-40/HIV-1 TAR complex.
From this NOE comparison, we conclude that the
peptides bind to the RNA in a similar manner.
However, without a structure for both peptides, it is dif-
ﬁcult to conclusively identify the structural or dynamics
basis for the difference in activity between the two
peptides.
DISCUSSION
The Tat–TAR interaction has long been considered a
target for the development of novel antivirals but the
difﬁculty of inhibiting RNA–protein interfaces with
small molecules has prevented the successful pre-clinical
or clinical development of Tat–TAR inhibitors
(3–19,32–34). To overcome these difﬁculties, our group
has focused on cyclic b-hairpin peptide mimics of Tat
protein, developed through a structural rationale
(20–23,35). We reasoned that the rigidity of these
pre-structured peptides would increase their selectivity,
compared to other ﬂexible RNA-binding peptide mimics
(3,4), and their larger molecular weight would allow more
potent and speciﬁc interactions compared to small organic
structures. Based on this rationale, we succeeded in de-
veloping cyclic peptide structural mimics of Tat protein
with nM afﬁnity for HIV TAR and with an in vivo
activity that makes them attractive antiviral leads
(22,23). In order to further improve their potency, we
extended them by 1, 2 or 4 amino acids, reasoning that
a longer hairpin would make more extensive contacts with
the single-stranded nucleotides in the apical loop than we
had previously observed in the structure of a lead
peptide-RNA complex (23). Some of the new peptides
(Table 3) were found to bind tightly to HIV-1 TAR, but
only when the hairpin was extended by 4 amino acids. For
this group of molecules, even small variations in the
peptide sequence led to relatively large changes in
activity, suggesting a speciﬁc interaction. The speciﬁcity
of the peptides for HIV TAR RNA is also demonstrated
by their ability to retain strong afﬁnity for the target even
in the presence of very large excess of tRNA.
Furthermore, when we compared binding for other
members of this family of cyclic peptides with various
mutated versions of HIV TAR, including mutation and
deletion of residues U23 and A35, we demonstrated that
the absence of a single critical nucleotide abolishes peptide
activity, lending additional evidence for the speciﬁcity of
these peptides (23). A second set of peptides were designed
based on the features of the more active library members,
and a molecule, KP-Z-41, emerged with sub-nanomolar
afﬁnity for HIV-1 TAR. An improvement >6-fold was
thus successfully obtained in binding activity.
We determined the structure of the KP-Z-41/TAR
complex in order to verify whether our rationale of ex-
tending the peptide to interact with the loop was correct
and to guide our next steps of peptide development. We
were surprised to discover that the additional residues did
not bring the peptide closer to the loop; instead, the
D-Pro-L-Pro end of the peptide hairpin extended away
from the RNA into solution. The structural reasons for
this effect were nonetheless very revealing. Interactions
between the peptide and the RNA interhelical junction
are nearly identical for KP-Z-41 and the previous lead
peptide L-22, at residues Arg7, Lys8 and Ile12. In order
to form these interactions, however, the peptide slides
down the major groove away from the apical loop and
pushes residues near the D-Pro-L-Pro template into
solution. Not only are the peptide-RNA interactions at
Ile12, Arg7 and Lys8 preferably formed over other
possible interactions near the D-Pro-L-Pro end of the
peptide, but they are also apparently favorable enough
to drive the increased afﬁnity of the peptide for the
RNA despite the entropic costs of leaving several hydro-
phobic residues (an isoleucine and both prolines) exposed
to solvent. The placement of these three critical residues
(Ile12, Arg7 and Lys8) should be regarded as the
minimum requirement for peptide mimics of Tat targeting
this HIV TAR conformation. Their requirement to
organize the RNA–peptide complex will be taken into
account in our future peptide designs and should be con-
sidered when designing small molecule ligands for TAR as
well.
Because of these unexpected changes in the peptide–
RNA interactions, Arg10 and Arg11 are the only
residues in the KP-Z-41/TAR structure positioned near
the loop, and only Arg11 forms a stable enough inter-
action to be detected by NOESY experiments, stacking
over G34 and A35. The placement of the disulﬁde
bridge used for reinforcing hairpin formation in
KP-Z-41 prohibits the direct arginine stacking with
RNA residue A35 that was seen in the L-22/TAR struc-
ture. Thus, interactions of the amino acids at the
C-terminal side of the KG turn are fairly weak and
should be optimized further to improve peptide binding.
Our future work on peptide design will focus on develop-
ment of new contacts at the apical loop based on
re-organization of the peptide, while maintaining
features that are shown in this study to be crucial for
speciﬁc HIV TAR binding. By fully understanding the
essential hydrophobic and polar interactions that lead to
strong binding activity, we should now be able to design
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intermolecular contacts at other locations in our peptide.
By moving the crucial Ile–Arg–Lys combination to new
locations within the peptide, we may be able to induce the
peptide to slide upwards along the major groove and reach
the apical loop of the RNA to form more extensive
contacts.
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